%PDF-1.4
1 0 obj
<< /Type /Catalog /Pages 2 0 R >>
endobj
2 0 obj
<< /Type /Pages /Kids [3 0 R] /Count 1 >>
endobj
3 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Contents 4 0 R /Resources << /Font << /F1 5 0 R >> >> >>
endobj
4 0 obj
<< /Length 1050 >>
stream
BT
/F1 24 Tf
50 750 Td
(GLP-1 Receptor Agonist Market Report) Tj
0 -40 Td
/F1 14 Tf
(Diabetes and Obesity Treatment Landscape) Tj
0 -30 Td
/F1 11 Tf
(GLP-1 receptor agonists have revolutionized the treatment) Tj
0 -15 Td
(of type 2 diabetes and obesity, with unprecedented demand) Tj
0 -15 Td
(driving supply constraints globally.) Tj
0 -30 Td
/F1 14 Tf
(Market Leaders:) Tj
0 -20 Td
/F1 11 Tf
(- Semaglutide (Ozempic/Wegovy): USD 21B revenue 2023) Tj
0 -15 Td
(- Tirzepatide (Mounjaro/Zepbound): Fastest launch ever) Tj
0 -15 Td
(- Liraglutide (Victoza/Saxenda): Established market leader) Tj
0 -15 Td
(- Dulaglutide (Trulicity): Strong US presence) Tj
0 -30 Td
/F1 14 Tf
(Clinical Development:) Tj
0 -20 Td
/F1 11 Tf
(- SURPASS trials: Tirzepatide superior A1C reduction) Tj
0 -15 Td
(- SELECT trial: CV risk reduction with semaglutide) Tj
0 -15 Td
(- STEP trials: Up to 22% body weight loss) Tj
0 -30 Td
/F1 14 Tf
(Market Forecast:) Tj
0 -20 Td
/F1 11 Tf
(GLP-1 market expected to exceed USD 100B by 2030) Tj
0 -15 Td
(driven by obesity indication expansion.) Tj
ET
endstream
endobj
5 0 obj
<< /Type /Font /Subtype /Type1 /BaseFont /Helvetica >>
endobj
xref
0 6
0000000000 65535 f 
0000000009 00000 n 
0000000058 00000 n 
0000000115 00000 n 
0000000266 00000 n 
0000001368 00000 n 
trailer
<< /Size 6 /Root 1 0 R >>
startxref
1447
%%EOF